Cyto-IL-15 Synergizes with the STING Agonist ADU-S100 To Eliminate Prostate Tumors and Confer Durable Immunity in Mouse Models

To determine whether thecombination of cytotopically modified interleukin-15 (cyto-IL-15) with the stimulator of interferon genes (STING) agonist, ADU-S100 could lead to both local and systemic anti-tumor effects, intratumoral administration of these agents was used in murine models of prostate cancer.